{"filing":{"accession_number":"0001193125-26-269734","cik":"0000791908","ticker":"XOMAP","company_name":"XOMA Royalty Corp","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"d143305d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312526269734/d143305d8k.htm"},"events":[{"id":10374,"run_id":9097,"accession_number":"0001193125-26-269734","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"XOMA Royalty Corp announced an expected closing date of July 14, 2026 for its previously announced acquisition by Ligand Pharmaceuticals under a Merger Agreement dated April 27, 2026, constituting a material update on the anticipated completion of a merger transaction that would result in a change of control of the registrant.","company_name":"XOMA Royalty Corp","ticker":"XOMAP","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6674,"accession_number":"0001193125-26-269734","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The disclosure announces an expected closing date (July 14, 2026) for a previously announced acquisition of XOMA Royalty Holdings Corporation by Ligand Pharmaceuticals under a Merger Agreement dated April 27, 2026. This constitutes a material update on M\u0026A activity — specifically the anticipated completion of a merger transaction that would result in a change of control of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:06:15.229507+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10375,"run_id":9097,"accession_number":"0001193125-26-269734","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The company announced a full redemption of all outstanding Series A and Series B Cumulative Perpetual Preferred Stock (984,000 and 1,760.5 shares respectively) at $25.00 per share plus accrued dividends, effective July 14, 2026, which will eliminate the preferred equity class and delist the preferred shares from Nasdaq.","company_name":"XOMA Royalty Corp","ticker":"XOMAP","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6675,"accession_number":"0001193125-26-269734","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a full redemption of all outstanding Series A and Series B Cumulative Perpetual Preferred Stock (984,000 and 1,760.5 shares respectively) at $25.00 per share plus accrued dividends, effective July 14, 2026. While this is a significant capital event affecting the company's capital structure and preferred shareholders, it does not fit neatly into the standard taxonomy categories. The redemption is material to investors as it eliminates an entire class of preferred equity and will delist the preferred shares from Nasdaq, but it is a routine redemption exercise under the Certificate of Designation rather than an earnings release, M\u0026A activity, impairment, or other more specific event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:06:15.229507+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6674,"accession_number":"0001193125-26-269734","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The disclosure announces an expected closing date (July 14, 2026) for a previously announced acquisition of XOMA Royalty Holdings Corporation by Ligand Pharmaceuticals under a Merger Agreement dated April 27, 2026. This constitutes a material update on M\u0026A activity — specifically the anticipated completion of a merger transaction that would result in a change of control of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:06:15.229507+00:00","company_name":"XOMA Royalty Corp","ticker":"XOMAP","filing_date":"2026-06-12"},{"id":6675,"accession_number":"0001193125-26-269734","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a full redemption of all outstanding Series A and Series B Cumulative Perpetual Preferred Stock (984,000 and 1,760.5 shares respectively) at $25.00 per share plus accrued dividends, effective July 14, 2026. While this is a significant capital event affecting the company's capital structure and preferred shareholders, it does not fit neatly into the standard taxonomy categories. The redemption is material to investors as it eliminates an entire class of preferred equity and will delist the preferred shares from Nasdaq, but it is a routine redemption exercise under the Certificate of Designation rather than an earnings release, M\u0026A activity, impairment, or other more specific event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:06:15.229507+00:00","company_name":"XOMA Royalty Corp","ticker":"XOMAP","filing_date":"2026-06-12"}]}